Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SanOrg34006 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SanOrg34006 | DRUG | - |
| LMW heparin | DRUG | - |
| Unfractionated heparin | DRUG | - |
| Vitamin K antagonist (VKA) | DRUG | - |
Inclusion Criteria: * Confirmed acute symptomatic DVT * Written informed consent Exclusion Criteria: * Legal lower age limitations * Patients with symptomatic pulmonary embolism * Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT * Other...
SanOrg34006 is an investigational small molecule being developed for the treatment of Deep Vein Thrombosis (DVT). It is a cardiovascular therapeutic that has completed a Phase 3 clinical trial evaluating its safety and efficacy in patients with this condition.
SanOrg34006 is being developed by Sanofi, a company traded under the ticker symbol SNY. The drug is an investigational small molecule intended for the treatment of Deep Vein Thrombosis, a cardiovascular condition.
SanOrg34006 is in Phase 3 clinical development. A Phase 3 trial, NCT00067093, has been completed, evaluating the drug's safety and efficacy in the treatment of Deep Vein Thrombosis. The drug remains investigational and is not yet approved.
SanOrg34006 has one completed Phase 3 clinical trial, NCT00067093, titled 'Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)'. The trial enrolled 1452 participants in the United States and was completed.
Yes, SanOrg34006 is also known as SR34006. The completed Phase 3 clinical trial NCT00067093 refers to the drug as SR34006 in its title, confirming that both names refer to the same investigational treatment for Deep Vein Thrombosis.